Heart failure & cardiomyopathies
Impact of Age on Long-Term Clinical Outcomes Following HeartMate 3 Left Ventricular Assist Device (LVAD) Implantation: Insights From the MOMENTUM 3 Trial
Corrected 23 Oct 2026: Measure wording clarified; no values changed.
Authors' conclusion
Age is associated with outcomes in HM3 patients, with younger individuals showing better survival and fewer bleeding events.
Study context
- Population
- HeartMate 3 LVAD recipients in the MOMENTUM 3 trial
- Participants
- 2,200 participants
- Comparison
- HM3 LVAD outcomes by age group
- Primary endpoint
- Survival and survival free of disabling stroke or reoperation
- Follow-up
- 2 years
Methodological detailsage-stratified
- Age-stratified
Primary result
As reported in the abstract
2-year survival
Each group vs <50 yearsHazard ratio (95% CI)P value
≥70 yearssurvival free of disabling stroke or reoperation: 70.5% vs 82.3%
1.46 (1.04–2.04), event not clearly stated
P = 0.028- 50-59 years · survival
- HR 1.16 (95% CI 0.77–1.75), event not clearly stated; P = 0.47
- 60-69 years · survival
- HR 1.76 (95% CI 1.21–2.57), event not clearly stated; P = 0.0033
- ≥70 years · survival
- HR 2.24 (95% CI 1.50–3.34), event not clearly stated; P < 0.0001
Safety
| Outcome | <50 years | ≥70 years | P value |
|---|---|---|---|
| GI bleeding≥70 years vs <50 years | 0.12 events per patient-year | 0.42 events per patient-year | P < 0.001 |
| Sepsis≥70 years vs <50 years | 0.12 EPPY | 0.16 EPPY | P = 0.035 |
| Driveline infection≥70 years vs <50 years · reduced in older | 0.29 EPPY | 0.12 EPPY | P < 0.001 |
| Hemorrhagic stroke<50 years vs ≥70 years | 0.045 EPPY | 0.028 EPPY | P = 0.027 |
Hemorrhagic stroke
- Stroke rates low overall
Original publication
Impact of Age on Long-Term Clinical Outcomes Following HeartMate 3 LVAD Implantation: Insights From the MOMENTUM 3 Trial. JACC Heart Fail. Published 29 June 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →